This article has been updated to reflect the correct proposed list price for Rozlytrek.
NEW YORK – The UK's National Institute for Health Care Excellence (NICE) on Thursday published a final draft guidance recommending the histology-independent use of entrectinib (Roche's Rozlytrek) through the Cancer Drugs Fund (CDF).